synchron.comHealthcare / Medical DevicesFounded: 2016Funding to Date: $118.41MM
Synchron has developed an endovascular brain computer interface that can access every corner of the brain using its natural highways, the blood vessels. Their breakthrough platform launches a new frontier for the treatment of neurological diseases: Neurointerventional Electrophysiology (Neuro EP). This company was founded in 2016 and is headquartered in Brooklyn, NY.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
12/15/2022 | Series C-1 | $872,072.00 | $xx.xx | $400.53MM | Alumni Ventures, Arch Venture Partners, Bezos Expeditions, Forepoint Capital Partners, Gates Frontier, Greenoaks, Id8 Investments, Khosla Ventures, Metis, Moore Strategic Ventures, Neurotechnology Investors, Project X, Reliance Digital Health Limited, Shanda Group, University Of Melbourne | |
Price per Share
$xx.xx
Shares Outstanding
36,777
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alumni Ventures, Arch Venture Partners, Bezos Expeditions, Forepoint Capital Partners, Gates Frontier, Greenoaks, Id8 Investments, Khosla Ventures, Metis, Moore Strategic Ventures, Neurotechnology Investors, Project X, Reliance Digital Health Limited, Shanda Group, University Of Melbourne
|
||||||
12/15/2022 | Series C | $74.13MM | $xx.xx | $400.53MM | Alumni Ventures, Arch Venture Partners, Bezos Expeditions, Forepoint Capital Partners, Gates Frontier, Greenoaks, Id8 Investments, Khosla Ventures, Metis, Moore Strategic Ventures, Neurotechnology Investors, Project X, Reliance Digital Health Limited, Shanda Group, University Of Melbourne | |
Price per Share
$xx.xx
Shares Outstanding
2,657,210
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alumni Ventures, Arch Venture Partners, Bezos Expeditions, Forepoint Capital Partners, Gates Frontier, Greenoaks, Id8 Investments, Khosla Ventures, Metis, Moore Strategic Ventures, Neurotechnology Investors, Project X, Reliance Digital Health Limited, Shanda Group, University Of Melbourne
|
||||||
06/03/2021 | Series B-1 | $3.87MM | $xx.xx | $139.83MM | Arani Bose, Forepont Capital Partners, General Advance, Id8 Investments, Khosla Ventures, Metis, Neurotechnology Inestors, Re.Mind Capital, Shanda Group, Subversive Capital, Thomas Reardon, University Of Melbourne | |
Price per Share
$xx.xx
Shares Outstanding
360,658
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Arani Bose, Forepont Capital Partners, General Advance, Id8 Investments, Khosla Ventures, Metis, Neurotechnology Inestors, Re.Mind Capital, Shanda Group, Subversive Capital, Thomas Reardon, University Of Melbourne
|
||||||
06/03/2021 | Series B | $36MM | $xx.xx | $139.83MM | Arani Bose, Forepont Capital Partners, General Advance, Id8 Investments, Khosla Ventures, Metis, Neurotechnology Inestors, Re.Mind Capital, Shanda Group, Subversive Capital, Thomas Reardon, University Of Melbourne | |
Price per Share
$xx.xx
Shares Outstanding
2,849,155
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Arani Bose, Forepont Capital Partners, General Advance, Id8 Investments, Khosla Ventures, Metis, Neurotechnology Inestors, Re.Mind Capital, Shanda Group, Subversive Capital, Thomas Reardon, University Of Melbourne
|
||||||
04/04/2017 | Series A | $3.54MM | $xx.xx | $14.16MM | Darpa, Neurotechnology Investors | |
Price per Share
$xx.xx
Shares Outstanding
1,770,224
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Darpa, Neurotechnology Investors
|